Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1657 1678 1682
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Non-Final OA | Janssen Biotech, Inc. |
| 18442934 | COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17997878 | DETECTION ASSAY FOR ANTI-SARS-COV-2 ANTIBODIES | Non-Final OA | The Regents of the University of California |
| 17293678 | MOLECULES AND METHODS FOR IMPROVED IMMUNODETECTION OF SMALL MOLECULES SUCH AS HISTAMINE | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 17618869 | TARGETS AND METHODS OF DIAGNOSING, MONITORING AND TREATING FRONTOTEMPORAL DEMENTIA | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18012798 | PROGNOSIS OF CHRONIC INFLAMMATORY DEMYELINATING POLY-NEUROPATHY | Non-Final OA | Katholieke Universiteit Leuven |
| 17488649 | SPR-BASED BINDING ASSAY FOR THE FUNCTIONAL ANALYSIS OF MULTIVALENT MOLECULES | Non-Final OA | Hoffmann-La Roche Inc. |
| 17265718 | TEST TO ASSESS LIVER DISEASE SEVERITY | Final Rejection | University of Cincinnati |
| 17575137 | SUBSTANCE P AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 17575120 | S100A9 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | Non-Final OA | Children's Hospital Medical Center |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy